A Phase 4 interventional study of pravastatin, valsartan, pravastatin+valsartan in Hypertension and High Cholesterol, sponsored by Gachon University Gil Medical Center. Completed at 1 site in Korea, Republic of. Open to participants aged 25 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-08-09.
Sponsored by Gachon University Gil Medical Center · Phase 4, Interventional, and Treatment
The investigators hypothesize that pravastatin combined with valsartan may have additive effects in hypertensive, hypercholesterolemic patients.
1,238 studies on the registry are indexed under Hypercholesterolemia; 110 are open to participants now.
This study's enrollment of 52 is below the median of 100 across 992 interventional studies indexed under Hypercholesterolemia.
Browse Hypercholesterolemia studies →Gachon University Gil Medical Center is the lead sponsor of 88 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: pravastatin, valsartan, pravastatin+valsartan
Drug: pravastatin, valsartan, pravastatin+valsartan
Drug: pravastatin, valsartan, pravastatin+valsartan
pravastatin 40 mg, valsartan 160 mg 8 weeks of treatment
flow-mediated dilation
Time frame: 8 weeks of treatment
insulin resistance
Time frame: 8 weeks of treatment
This study is completed, as verified in Oct 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gachon University Gil Medical Center